Abstract
Objectives
The aim of the study was to determine the extent of inter-individual variation in clearance of intravenous morphine in children and to establish which factors are responsible for this variation.
Methods
A systematic literature review was performed to identify papers describing the clearance of morphine in children. The following databases were searched: Medline, Embase, International Pharmaceutical Abstracts, CINAHL, and Cochrane library. From the papers, the range in plasma clearance and the coefficient of variation (CV) in plasma clearance were determined.
Results
Twenty-eight studies were identified. After quality assessment, 20 studies were included. Only 10 studies gave clearance values for individual patients. The majority of the studies were in critically ill patients. Inter-individual variability of morphine clearance was observed in all age groups, but greatest in critically ill neonates (both preterm and term) and infants. In critically ill patients, the CV was 16–9 7 % in preterm neonates, 24–87 % in term neonates, 35 and 134 % in infants, 39 and 55 % in children, and 74 % in adolescents. The CV was 37 and 44 % respectively in non-critically ill neonates and infants. The mean clearance was higher in children (32 and 52 ml min-1 kg-1) than in neonates (2 to 16 ml min-1 kg-1).
Conclusions
Large inter-individual variation was seen in morphine clearance values in critically ill neonates and infants.
Similar content being viewed by others
Introduction
Morphine is a naturally occurring opioid alkaloid. It is the first choice analgesic for severe pain and can be used for preoperative sedation. Morphine can be administered via different routes intravenously (IV), intramuscularly (IM), subcutaneously (SC), orally, and rectally. There are two major formulations of oral morphine: immediate release, which has extensive inter-individual variation for bioavailability and controlled release morphine, which is less variable. Bioavailability is approximately 30–40 % [1].
Dosing varies according to the age, route of administration, and is based on body weight [2–4]. Due to patients’ varied response to pain, morphine dose is usually titrated according to clinical response. Paediatric dosing for drugs is sometimes determined from adult pharmacokinetic studies. However, results from adults are difficult to extrapolate to children, because the physiological makeup of the two age groups is different. Pharmacokinetic studies in children therefore help to ensure that the appropriate drug dose is administered. Doses are usually calculated from mean pharmacokinetic values. There is however often significant variability in pharmacokinetics due to factors such as age [5], weight [6], disease [7], and ethnicity/genotype [8]. Recent advances in research has resulted in the development of PK–models to ensure the appropriate individualisation of dosing in children [9].
We have previously evaluated inter-individual variation in the clearance of midazolam [10]. We wished to explore inter-individual variation in morphine clearance in paediatric patients and we therefore performed a systematic review of pharmacokinetic studies in paediatric patients involving morphine. The metabolite morphine-6-glucuronide (M6G) is more potent as an analgesic than morphine itself. We therefore also looked at M6G to morphine ratios.
Methods
A systematic literature search was performed to identify all papers describing the clearance of morphine in children. The following databases were utilised; MEDLINE (1946 to May 2013), EMBASE (1974 to May 2013), International Pharmaceutical Abstracts (1970 to April 2013), CINAHL, and Cochrane Library. The databases were searched separately and combined together to remove duplications. The search strategy included all languages and involved the keywords “morphine AND “child*” OR “p*ediatric* OR “infant*” OR “new-born*” OR “neonate*” OR “adolescent*” [11] AND “pharmacokinetic*” OR “clearance” OR “half-life” OR “absorption” OR “distribution” OR “metabolism” OR “elimination” OR *”.
Inclusion criteria were original research studies assessing the pharmacokinetics of morphine in children up to the age of 18 years. We excluded the following: review articles, editorials, conference abstracts, studies in adults aged 18 years and over, and studies that involved adults and paediatric patients where the paediatric data was not presented separately. Studies in which morphine was not administered intravenously were also excluded.
Data such as, number of patients, ethnicity, dose, and clearance were extracted. The mean/median clearance, as well as both the minimum and maximum clearance values were noted. The variation ratio was calculated from the range of clearance (maximum clearance divided by the minimum clearance).The coefficient of variation (CV) was extracted from the paper if given. If individual data was presented, then the CV was calculated using the formula [10, 12].
which allows for the fact that clearance is usually log normally distributed in children. If individual data was not available, then CV was estimated by dividing the standard deviation by the mean of clearance, i.e., normal distribution assumed. The variation ratio for M6G/M was calculated by dividing the maximum M6G/M by the minimum M6G/M. Patients were divided into two groups: (1) critically ill if they were in an intensive care unit and (2) non-critically ill which included other groups. We also contacted original authors by email if their paper did not give the full range of clearance values but gave mean clearance values.
Results
A total of 2040 articles were identified, but only 28 articles (studies) met the inclusion criteria [5, 7, 13–38] (Fig. 1).
Eight studies were excluded after quality assessment (Supplementary table 3) [19, 23, 29–31, 35–37]. For one study, some of the data were excluded [5]. A total of 20 studies were included after quality assessment.
The majority of the studies (19) used non-compartmental methods. Only one used a two-compartmental model [34]. Ethnicity was not described in any study. The CV was not stated in any study. Ten studies provided individual data allowing calculation of CV [5, 7, 13–16, 18, 24, 28, 32]. In six studies, only the standard deviation (SD) was reported, and therefore, CV was estimated, assuming normal distribution [17, 20–22, 26, 34]. Three studies did not report either SD or CV of morphine clearance [25, 27, 33].
All the studies, except two, involved critically ill patients [5, 27]. Thirteen studies reported morphine clearance in 228 critically ill neonates (Table 1) [5, 13–18, 20–22, 24–26].
Details of the administration of morphine and the number of blood samples collected to calculate clearance are given in Supplementary Table 1.
Nine of the neonatal studies were in preterm neonates (n = 166) with CV ranging from 16 to 97 %. The CV for term neonates (n = 62) varied between 24 and 87 %. There was 2–14-fold inter-individual variation of clearance in preterm neonates and 3–20-fold variation in term neonates. The range in clearance is shown in Fig. 2.
There were four studies involving 53 infants (Table 2) [24, 25, 27, 28].
Two of these studies involved both critically ill and non-critically ill patients (Table 3).
One of these studies involved both term neonates and infants with CV of 37 and 44 %, respectively [5]. The other study involving infants did not report the CV. However, variation ratios in these studies were twofold and threefold [5, 27]. The CV of morphine clearance in critically ill infants was 35 and 134 %. The variation ratio in studies involving critically ill infants was between 2- and 11-fold.
Two studies reported clearance in 12 critically ill children [28, 32]. The CV in these studies was 39 and 55 %. These studies gave the full range of clearance for inter-individual children. The variation ratio of clearance was threefold for both studies. Only one study involved adolescents. The four critically ill adolescents had CV of 74 % and variation ratio of threefold [32].
Three studies involved a combination of more than one age group [7, 33, 34]. The highest CV of 39 % was in a study involving patients aged 6–19 years, whilst the lowest CV of 25 % was in patients aged 7 months–7 years. The degree of variability in clearance was between 2- and 10-fold. The coefficients of variation in different age groups are summarised in Table 4.
Three studies reported the ratio of M6G to morphine (Supplementary table 2) [18, 33, 38]. The variation ratio in neonates ranged between 4- and 33-fold. One study in infants reported variation ratio of 12-fold.
Discussion
Inter-individual variation was greatest in critically ill neonates and infants. Inter-individual variation was lowest in non-critically ill patients. The variation ratio in clearance in critically ill neonates ranged from 2- to 20-fold with the coefficient of variation going up to 96 %. In infants, the variation ratio ranged from 2- to 11-fold with the coefficient of variation up to 134 %. In contrast, the variation ratio in non-critically ill patients and critically ill children and adolescents was less than fourfold (with the exception of one study in critically ill children where it was almost 10-fold).
Intravenous morphine is administered as a fixed dose bolus (50 μg/kg in neonates and 100 μg/kg in infants and children up to the age of 12 years [4]. It is then given as an intravenous infusion with a fourfold variation in dosage in neonates (5–20 μg/kg/h) and lower variation in infusion rates in infants (10–30 μg/kg/h) and children (20–30 μg/kg/h). The dose is then titrated according to clinical response. Titration of dose is essential due to the large inter-individual variation in clearance. The considerable variation in M6G/M ratio especially in neonates suggests that the variation in dosage requirements in order to achieve adequate pain relief is far greater than that currently recommended.
The large inter-individual variation in critically ill neonates and infants is similar to our previous study on inter-individual variation in midazolam clearance in children. In contrast, there was, however, less inter-individual variation in critically ill children and adolescents with morphine than with midazolam. Critically ill patients tend to have impaired renal and hepatic function. Hepatic blood flow and hepatocellular function are altered, and consequently, hepatic clearance of morphine can be impaired [39]. Critically ill children are also at risk of acute renal failure. Impairment of morphine clearance prolongs the drug half-life and accumulation of drugs may occur, leading to toxicity [40]. Conditions such as sepsis, major surgery, and use of nephrotoxic drugs can damage the kidneys thereby altering the pharmacokinetic parameters of morphine [41].
In conclusion, large inter-individual variation was seen in morphine clearance values in critically ill neonates and infants.
References
Hand C, Moore R, McQuay H, Allen M, Sear J (1987) Analysis of morphine and its major metabolites by differential radioimmunoassay. Ann Clin Biochem 24:153–160
Baber N, Pritchard D (2003) Dose estimation for children. Br J Clin Pharmacol 56(5):489–493
Anderson BJ, Holford NH (2013) Understanding dosing: children are small adults, neonates are immature children. Arch Dis Child 98(9):737–744
Joint Formulary Committee. British national formulary for children (2014) British Medical Association and Royal Pharmaceutical Society,2014, london
Pokela M, Olkkola K, Seppälä T, Koivisto M (1993) Age-related morphine kinetics in infants. Dev Pharmacol Ther 20(1–2):26
Knibbe CA, Krekels EH, van den Anker JN, DeJongh J, Santen GW, van Dijk M, Simons SH, van Lingen RA, Jacqz-Aigrain EM, Danhof M (2009) Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet 48(6):371–385
Dagan O, Klein J, Bohn D, Barker G, Koren G (1993) Morphine pharmacokinetics in children following cardiac surgery: effects of disease and inotropic support. J Cardiothorac Vasc Anesth 7(4):396–398
Klepstad P, Dale O, Skorpen F, Borchgrevink PC, Kaasa S (2005) Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand 49(7):902–908. doi:10.1111/j.1399-6576.2005.00772.x
Admiraal R, van Kesteren C, Boelens JJ, Bredius RG, Tibboel D, Knibbe CA (2014) Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling. Arch Dis Child 99(3):267–272
Altamimi MI SH, Choonara I (2014) Inter-individual variation in midazolam clearance in children. Arch Dis Child 0:1-6
Kastner M, Wilczynski NL, Walker-Dilks C, McKibbon KA, Haynes B (2006) Age-specific search strategies for Medline. J Med Internet Res 8(4):e25
Pang W-K, Leung P-K, Huang W-K, Liu W (2005) On interval estimation of the coefficient of variation for the three-parameter Weibull, lognormal and gamma distribution: a simulation-based approach. Eur J Oper Res 164(2):367–377
Hartley R, Green M, Quinn M, Levene M (1993) Pharmacokinetics of morphine infusion in premature neonates. Archives of disease in childhood 69 (1 Spec No):55-58
Mikkelsen S, Feilberg V, Christensen C, Lundstrøm K (1994) Morphine pharmacokinetics in premature and mature newborn infants. Acta Paediatr 83(10):1025–1028
Barrett D, Elias‐Jones A, Rutter N, Shaw P, Davis S (1991) Morphine kinetics after diamorphine infusion in premature neonates. Br J Clin Pharmacol 32(1):31–37
Chay PC, Duffy BJ, Walker JS (1992) Pharmacokinetic-pharmacodynamic relationships of morphine in neonates. Clin Pharmacol Ther 51(3):334–342
Saarenmaa E, Neuvonen PJ, Rosenberg P, Fellman V (2000) Morphine clearance and effects in newborn infants in relation to gestational age&ast. Clin Pharmacol Ther 68(2):160–166
Barrett D, Barker D, Rutter N, Pawula M, Shaw P (1996) Morphine, morphine‐6‐glucuronide and morphine‐3‐glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. Br J Clin Pharmacol 41(6):531–537
Choonara I, McKay P, Hain R, Rane A (1989) Morphine metabolism in children. Br J Clin Pharmacol 28(5):599–604
Geiduschek JM, Lynn AM, Bratton SL, Sanders JC, Levy FH, Haberkern CM, O'Rourke PP (1997) Morphine pharmacokinetics during continuous infusion of morphine sulfate for infants receiving extracorporeal membrane oxygenation. Crit Care Med 25(2):360–364
Bhat R, Chari G, Gulati A, Aldana O, Velamati R, Bhargava H (1990) Pharmacokinetics of a single dose of morphine in preterm infants during the first week of life. J Pediatr 117(3):477–481
Scott CS, Riggs KW, Ling EW, Fitzgerald CE, Hill ML, Grunau RV, Solimano A, Craig KD (1999) Morphine pharmacokinetics and pain assessment in premature newborns. J Pediatr 135(4):423–429
Lynn A, Nespeca M, Bratton S, Strauss S, Shen D (1998) Clearance of morphine in postoperative infants during intravenous infusion: the influence of age and surgery. Anesth Analg 86(5):958–963
Lynn AM, Slattery JT (1987) Morphine pharmacokinetics in early infancy. Anesthesiology 66(2):136–139
McRorie TI, Lynn AM, Nespeca MK, Opheim KE, Slattery JT (1992) The maturation of morphine clearance and metabolism. Arch Pediatr Adolesc Med 146(8):972
Koren G, Butt W, Chinyanga H, Soldin S, Tan Y-K, Pape K (1985) Postoperative morphine infusion in newborn infants: assessment of disposition characteristics and safety. J Pediatr 107(6):963–967
Róka A, Melinda KT, Vásárhelyi B, Machay T, Azzopardi D, Szabó M (2008) Elevated morphine concentrations in neonates treated with morphine and prolonged hypothermia for hypoxic ischemic encephalopathy. Pediatrics 121(4):e844–e849
Olkkola KT, Maunuksela E-L, Korpela R, Rosenberg PH (1988) Kinetics and dynamics of postoperative intravenous morphine in children. Clin Pharmacol Ther 44(2):128–136
Choonara I, Lawrence A, Michalkiewicz A, Bowhay A, Ratcliffe J (1992) Morphine metabolism in neonates and infants. Br J Clin Pharmacol 34(5):434–437
Lynn AM, Nespeca MK, Bratton SL, Shen DD (2003) Ventilatory effects of morphine infusions in cyanotic versus acyanotic infants after thoracotomy. Pediatr Anesth 13(1):12–17
Shelly M, Cory E, Park G (1986) Pharmacokinetics of morphine in two children before and after liver transplantation. Br J Anaesth 58(11):1218–1223
Nahata M, Miser A, Miser J, Reuning R (1985) Variation in morphine pharmacokinetics in children with cancer. Dev Pharmacol Ther 8(3):182
Collins JJ, Geake J, Grier HE, Houck CS, Thaler HT, Weinstein HJ, Twum-Danso NY, Berde CB (1996) Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. J Pediatr 129(5):722–728
Dampier CD, Setty B, Logan J, Ioli JG, Dean R (1995) Intravenous morphine pharmacokinetics in pediatric patients with sickle cell disease. J Pediatr 126(3):461–467
Robie IC, Kellner JD, Coppes MJ, Shaw D, Brown E, Good C, O'brodovich H, Manson D, Olivieri NF, Zipursky A (1992) Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. Pediatr Hematol-Oncol 9(4):317–326
Mashayekhi SO, Ghandforoush‐Sattari M, Routledge PA, Hain RD (2009) Pharmacokinetic and pharmacodynamic study of morphine and morphine 6‐glucuronide after oral and intravenous administration of morphine in children with cancer. Biopharm Drug Dispos 30(3):99–106
Hartley R, Quinn M, Green M, Levene M (1993) Morphine glucuronidation in premature neonates. Br J Clin Pharmacol 35(3):314
Bouwmeester N, Van Den Anker J, Hop W, Anand K, Tibboel D (2003) Age‐and therapy‐related effects on morphine requirements and plasma concentrations of morphine and its metabolites in postoperative infants. Br J Anaesth 90(5):642–652
Berkenstadt H, Segal E, Mayan H, Almog S, Rotenberg M, Perel A, Ezra D (1999) The pharmacokinetics of morphine and lidocaine in critically ill patients. Intensive Care Med 25(1):110–112
Rudin Å, Lundberg JF, Hammarlund-Udenaes M, Flisberg P, Werner MU (2007) Morphine metabolism after major liver surgery. Anesth Analg 104(6):1409–1414
Bodenham A, Shelly M, Park G (1988) The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin Pharmacokinet 14(6):347–373
Funding
None
Competing interests
None
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(DOCX 58 kb)
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Altamimi, M.I., Choonara, I. & Sammons, H. Inter-individual variation in morphine clearance in children. Eur J Clin Pharmacol 71, 649–655 (2015). https://doi.org/10.1007/s00228-015-1843-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-015-1843-x